B-Cell Maturation Antigen-Targeted Therapy Enables HLA-Incompatible Combined Haploidentical Stem-Cell and Kidney Transplantation (KIDNEY WEEK 2026) - Oct 2, 2026 - Abstract #FR-PO1212; Pres time: Oct 23, 2026; 10:00 AM - 12:00 PM; Location: Exhibit Hall A, Convention Center; "Despite treatment with daratumumab, bortezomib, dexamethasone, and lenalidomide, she progressed to ESKD by July 2022. She continued daratumumab-based therapy into 2023 in addition to venetoclax, achieving a 90% reduction in light chains...Therapy was transitioned to elranatamab, an anti-BCMA bispecific antibody, to deepen myeloma response and reduce DSAs...Mild acute cutaneous graft-versus-host disease developed but resolved with steroids and ruxolitinib...This case highlights the potential of BCMA-targeted therapy in desensitization to overcome HLA incompatibility in highly sensitized candidates waiting for a transplant. Timeline from the diagnosis of multiple myeloma, the combined kidney and stem cell transplant, and 9 months post-transplant."
Graft versus Host Disease • Hematological Malignancies • Immunology • Multiple Myeloma • Solid Organ Transplantation • Transplantation
|
|
Kassem Safa; Leonardo V. Riella; Andrew J. Yee; Vikram Pattanayak; Yi-Bin Chen
|